Citadel Advisors
CALT

Citadel Advisors’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Citadel Advisors’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,400
Closed -$250K – 15547
2024
Q2 		$250K Sell
6,400
-3,200
-33% -$88K ﹤0.01% 9500
2024
Q1 		$208K Sell
9,600
-400
-4% -$8.9K ﹤0.01% 10248
2023
Q4 		$258K Buy
10,000
+4,500
+82% +$84.3K ﹤0.01% 9462
2023
Q3 		$100K Buy
5,500
+400
+8% +$6.92K ﹤0.01% 10893
2023
Q2 		$80.1K Sell
5,100
-7,900
-61% -$167K ﹤0.01% 11254
2023
Q1 		$311K Buy
13,000
+9,100
+233% +$182K ﹤0.01% 9307
2022
Q4 		$68.4K Buy
+3,900
New +$62.9K ﹤0.01% 11734
2022
Q1 		– Sell
-30,600
Closed -$758K – 14812
2021
Q4 		$758K Buy
+30,600
New +$615K ﹤0.01% 8625

Other funds holding CALT

CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MTIC
Missouri Trust & Investment Company Springfield, Missouri $341M AUM 17.31% 1-Year Est. Return

Citadel Advisors's CALT Position: Q2 2024 in Review

Citadel Advisors sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q2 2024, closing a stake of 14,594 shares — an estimated $401K sold.

Citadel Advisors first reported a position in CALT in Q2 2020 and held it in 7 quarters. The position peaked at $1.48M in Q2 2020. 18 funds tracked by Wall St. Rank hold CALT as of Q2 2024.

  • Citadel Advisors reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 14,594 Calliditas Therapeutics AB American Depositary Shares shares in Q2 2024, an estimated $401K.
  • Citadel Advisors first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 7 quarters.
  • Citadel Advisors's Calliditas Therapeutics AB American Depositary Shares position peaked at $1.48M in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.